Multi-center, Prospective, Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule) Add-on to Statin Therapy in Patients Who Have History of Acute Myocardial Infarction and Are Diagnosed With Metabolic Syndrome

Trial Profile

Multi-center, Prospective, Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule) Add-on to Statin Therapy in Patients Who Have History of Acute Myocardial Infarction and Are Diagnosed With Metabolic Syndrome

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Fenofibrate (Primary)
  • Indications Metabolic syndrome
  • Focus Adverse reactions
  • Sponsors Daewoong Pharmaceutical
  • Most Recent Events

    • 25 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2014.
    • 25 Oct 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Sep 2014.
    • 19 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top